이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

2026년 11월 9일 업데이트: Fondazione Italiana Linfomi - ETS

An Observational Cohort Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.

In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.

Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.

We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.

연구 개요

상태

아직 모집하지 않음

정황

연구 유형

관찰

등록 (추정된)

500

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.

설명

Inclusion criteria:

General Inclusion Criteria:

  • Histologically confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
  • Age ≥ 18 years at the time of BTKi-based treatment initiation.
  • Patients who are able to understand the nature and objectives of the study and who have provided written informed consent, approved by the Independent Ethics Committee (IEC), for participation in the observational study.

For the retrospective enrollment group:

In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:

● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.

For the prospective enrollment group:

In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:

● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.

Exclusion criteria:

  • Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
  • Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
  • Inability or unwillingness to provide written informed consent, where required by applicable ethical and regulatory requirements.
  • Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: CROSS_SECTIONAL

코호트 및 개입

그룹/코호트
Retrospective enrollment group

Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96.

Prospective enrollment group

Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Best overall response
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Progression-free survival (PFS)
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Overall survival (OS)
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Event-free survival (EFS)
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Time to next treatment (TTNT)
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the initiation of a NALT.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Duration of response (DOR)
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Non-relapse mortality (NRM)
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as death without prior relapse or progression

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
POD24
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD)

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of adverse events
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of deaths
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

2차 결과 측정

결과 측정
측정값 설명
기간
Treatment duration
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment discontinuation
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment modifications
기간: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Frequency and reasons for dose reductions, interruptions and other modifications.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Marco Ladetto, MD, S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 3월 1일

기본 완료 (추정된)

2042년 3월 1일

연구 완료 (추정된)

2042년 3월 1일

연구 등록 날짜

최초 제출

2026년 11월 9일

QC 기준을 충족하는 최초 제출

2026년 11월 9일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • FIL_MANTLE-FIRST-BTKi

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .